Revolutionising healthcare with peptide-based therapies in specialist therapeutic areas

ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality Bio-pharma company that discovers and develops peptide-based therapeutics. The Company is headquartered in London with its R&D team, ImmuPharma Biotech, based in France.

The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class immune “restorer” for the treatment of autoimmune diseases and is in Phase 3 for SLE (Lupuzor™ is the disease trademark).

Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action, based on the P140 platform technology.

ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 study for Lupuzor™ and commercialise in the US.

4 core lead assets, 2 at late clinical stage

Lupuzor™

Autoimmunity

Lupus

Status
Phase 3 study (pivotal)

Study start
2023/24

P140

Inflammation

CIDP

Status
Phase 2/3 adapative (pivotal)

Study start
TBC

BioAMB

Anti-infection

Severe Fungal infection

Status
Late pre-clinical

Partnering
TBC

BioCIN

Anti-infection

Severe Bacterial infection

Status
Late pre-clinical

Partnering
TBC

Visit our pipeline page

Why Invest in ImmuPharma?

  • A rich portfolio with 2 highly attractive late-stage clinical indications – SLE & CIDP
  • Near-term business development opportunities across all programs
  • Innovative P140 Bio-drug platform has the potential in several autoimmune diseases and life cycle management through it’s second generation P140

Key progress

All announcements

Share Price

Market Cap

15 minute delayed share price provided by Hemscott Group Limited Disclaimer

Share Price - more details

Market Commentary

Professional advisers

Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
www.sparkadvisorypartners.com

Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us

Joint Broker
Si Capital Limited
info@sicapital.co.uk

Public Relations & Investor Relations
lisa.baderoon@immupharma.com

Auditors
Crowe LLP

Legal Representatives
Broadfield UK
London, U.K.

Badertscher Rechtsanwälte AG
Zurich, Switzerland

Patent Agents
Haseltine Lake Kempner LLP, UK

Manufacturers
Bachem (Bioglucagon)
BCN